@article{70c3cf36e9434f31b57ce972137d1541,
title = "A Call to Action for New Global Approaches to Cardiovascular Disease Drug Solutions",
abstract = "While we continue to wrestle with the immense challenge of implementing equitable access to established evidence-based treatments, substantial gaps remain in our pharmacotherapy armament for common forms of cardiovascular disease including coronary and peripheral arterial disease, heart failure, hypertension, and arrhythmia. We need to continue to invest in the development of new approaches for the discovery, rigorous assessment, and implementation of new therapies. Currently, the time and cost to progress from lead compound/product identification to the clinic, and the success rate in getting there reduces the incentive for industry to invest, despite the enormous burden of disease and potential size of market. There are tremendous opportunities with improved phenotyping of patients currently batched together in syndromic {"}buckets.{"} Use of advanced imaging and molecular markers may allow stratification of patients in a manner more aligned to biological mechanisms that can, in turn, be targeted by specific approaches developed using high-throughput molecular technologies. Unbiased {"}omic{"} approaches enhance the possibility of discovering completely new mechanisms in such groups. Furthermore, advances in drug discovery platforms, and models to study efficacy and toxicity more relevant to the human disease, are valuable. Re-imagining the relationships among discovery, translation, evaluation, and implementation will help reverse the trend away from investment in the cardiovascular space, establishing innovative platforms and approaches across the full spectrum of therapeutic development.",
keywords = "atherosclerosis, cardiovascular system, drug discovery, drug therapy, heart failure, organoids, precision medicine, therapeutics",
author = "Figtree, {Gemma A.} and Keith Broadfoot and Barbara Casadei and Robert Califf and Filippo Crea and Drummond, {Grant R.} and Freedman, {Jane E.} and Guzik, {Tomasz J.} and David Harrison and Hausenloy, {Derek J.} and Hill, {Joseph A.} and Januzzi, {James L.} and Kingwell, {Bronwyn A.} and Lam, {Carolyn S.P.} and MacRae, {Calum A.} and Frank Misselwitz and Tetsuji Miura and Ritchie, {Rebecca H.} and MacIej Tomaszewski and Wu, {Joseph C.} and Junjie Xiao and Faiez Zannad",
note = "Funding Information: G.A.F. reports grants from National Health and Medical Research Council (Australia), personal fees from CSL, and grants from Abbott Diagnostic outside the submitted work. In addition, G.A.F. has a patent Biomarkers and Oxidative Stress awarded USA May 2017 (US9638699B2) issued to Northern Sydney Local Health District. Dr B.C. reports in-kind research support from Roche Diagnostics and iRhythm, outside the submitted work. Dr R.C. reports personal fees from Verily, Google Health, and Cytokinetics, during the conduct of the study and outside the submitted work. Dr F.C. reports personal fees from Amgen, Astra Zeneca, Servier, and BMS, outside the submitted work. Dr J.E.F., Dr D.H., Dr D.J.H., Dr J.A.H., Dr T.M., Dr M.T., and Dr J.X. have nothing to disclose. Dr G.R.D. and Dr R.H.R. reports grants from National Health and Medical Research Council (Australia), Dr T.G. reports grants and personal fees from Oxford University Press, grants and personal fees from Bayer AG and Merck, outside the submitted work. Dr J.J. reports grants and personal fees from Roche, grants, personal fees, and other contributions from Novartis, grants from Innolife, grants from Applied Therapeutics, personal fees from Abbott, other contributions from Bayer, Siemens, Abbvie, Amgen, and Imbria Pharmaceuticals, during the conduct of the study. Dr B.A.K. reports other contributions from CSL Ltd, outside the submitted work. Dr C.S.P.L. is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Boston Scientific, Bayer, Roche Diagnostics, AstraZeneca, Medtronic, and Vifor Pharma; has served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Boston Scientific, Bayer, Roche Diagnostics, AstraZeneca, Medtronic, Vifor Pharma, Novartis, Amgen, Merck, Janssen Research & Development LLC, Menarini, Boehringer Ingelheim, Novo Nordisk, Abbott Diagnostics, Corvia, Stealth BioTherapeutics, JanaCare, Biofourmis, Darma, Applied Therapeutics, MyoKardia, Cytokinetics, WebMD Global LLC, Radcliffe Group Ltd and Corpus; and serves as co-founder and non-executive director of Us2.ai. Dr C.A.M. reports grants from NIH, American Heart Association, Verily, Astra Zeneca, Quest Diagnostics, Apple, Pfizer, Bayer, BMS, personal fees from Clarify Health Solutions, Foresite Labs, other contributions from Atman Health, outside the submitted work. In addition, Dr C.A.M. has a patent Genetic testing in cardiomyopathies with royalties paid to Partners Health Care, a patent Training cytometry data to refine disease pending, a patent Scalable cellular physiology to refine disease pending, and a patent Annotating small molecule function using phenotypic profiling pending. Dr F.M. reports other contributions from Bayer AG, outside the submitted work. Dr J.C.W. reports grants from National Institutes of Health. Dr F.Z. reports personal fees from Janssen, Novartis, Boston Scientific, Amgen, CVRx, other contributions from cardiorenal, personal fees from AstraZeneca, Vifor Fresenius, Cardior, Cereno pharmaceutical, Applied Therapeutics, Merck, other contributions from CVCT, personal fees from BAYER, Cellprothera, Owkin, Boehringer, Myokardia, Corvidia, and other contributions from G3 pharmaceuticals, outside the submitted work. Publisher Copyright: {\textcopyright} 2021 Lippincott Williams and Wilkins. All rights reserved.",
year = "2021",
month = jul,
day = "13",
doi = "10.1161/CIR.0000000000000981",
language = "English (US)",
volume = "144",
pages = "159--169",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "2",
}